Clinical trials: Drug Resistant Partial Onset Seizure, open to volunteers

Focal Epilepsy

Long-term Safety and Tolerability of BHV-7000

• Enrolling by invitation
• Age: 18 to 75 years
• Phase 2

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

Trial name

NCT06443463

Testing

BHV-7000

Where

283 sites in United States, Argentina and 25 more

Volunteers

660 people

Sponsor

Biohaven Therapeutics Ltd.